Suppr超能文献

一种用于Ⅱ期结肠癌患者根治性切除术后复发的新型预后预测模型。

A novel prognostic prediction model for recurrence in patients with stage II colon cancer after curative resection.

作者信息

Saso Kazuhiro, Myoshi Norikatsu, Fujino Shiki, Takenaka Yuya, Takahashi Yusuke, Nishimura Junichi, Yasui Masayoshi, Ohue Masayuki, Tokuoka Masayoshi, Ide Yoshito, Takahashi Hidekazu, Haraguchi Naotsugu, Hata Taishi, Matsuda Chu, Mizushima Tsunekazu, Doki Yuichiro, Mori Masaki

机构信息

Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.

Department of Surgery, Osaka International Cancer Institute, Osaka, Osaka 537-8511, Japan.

出版信息

Mol Clin Oncol. 2018 Dec;9(6):697-701. doi: 10.3892/mco.2018.1733. Epub 2018 Oct 4.

Abstract

The present study aimed to clarify the risk factors for recurrence of stage II colon cancer in patients and to determine possible treatment options for postoperative adjuvant chemotherapy. A prediction model for recurrence in patients with stage II colon cancer after curative surgical resection was developed. The present study retrospectively investigated 436 patients who underwent curative resection for stage II colon cancer at Osaka International Cancer Institute and Yao Municipal Hospital between 2004 and 2012. Several clinicopathological factors were examined and the Cox regression model was used to develop a prediction model for recurrence. The prediction model was validated in an independent group of 213 patients who underwent surgery at Osaka University Hospital between 2001 and 2012. Univariate analysis revealed that preoperative serum carcinoembryonic antigen level, preoperative obstruction, tumor invasion, lymphatic invasion and venous invasion were significantly correlated with disease-free survival. Using these variables, a classification and regression tree was constructed as a prediction model. The prediction models were validated by external datasets in an independent patient group. The concordance indices for DFS after current surgical resection were 0.675 in the learning set and 0.552 in the validation set. To conclude, a novel, reliable and personalized prognostic model was developed to predict recurrence in patients with stage II colon cancer, which may help clinicians to determine and perform adjuvant chemotherapy.

摘要

本研究旨在阐明Ⅱ期结肠癌患者复发的危险因素,并确定术后辅助化疗的可能治疗方案。建立了Ⅱ期结肠癌患者根治性手术切除后复发的预测模型。本研究回顾性调查了2004年至2012年间在大阪国际癌症研究所和八尾市立医院接受Ⅱ期结肠癌根治性切除的436例患者。检查了几个临床病理因素,并使用Cox回归模型建立复发预测模型。该预测模型在2001年至2012年间于大阪大学医院接受手术的213例独立患者组中进行了验证。单因素分析显示,术前血清癌胚抗原水平、术前梗阻、肿瘤侵犯、淋巴管侵犯和静脉侵犯与无病生存期显著相关。利用这些变量构建了分类回归树作为预测模型。预测模型在独立患者组的外部数据集中进行了验证。当前手术切除后DFS的一致性指数在学习集中为0.675,在验证集中为0.552。总之,开发了一种新颖、可靠且个性化的预后模型来预测Ⅱ期结肠癌患者的复发,这可能有助于临床医生确定并实施辅助化疗。

相似文献

1
A novel prognostic prediction model for recurrence in patients with stage II colon cancer after curative resection.
Mol Clin Oncol. 2018 Dec;9(6):697-701. doi: 10.3892/mco.2018.1733. Epub 2018 Oct 4.
2
Development of a novel prediction model for recurrent stage II colon cancer.
Surg Today. 2020 Apr;50(4):389-395. doi: 10.1007/s00595-019-01897-4. Epub 2019 Nov 28.
3
Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection.
ESMO Open. 2016 May 23;1(3):e000052. doi: 10.1136/esmoopen-2016-000052. eCollection 2016.
7
[Analysis of prognostic factors after radical resection in 628 patients with stage II or III colon cancer].
Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):212-6. doi: 10.3760/cma.j.issn.0253-3766.2013.03.011.
8
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13.

本文引用的文献

1
Gastroenterological surgery in Japan: The past, the present and the future.
Ann Gastroenterol Surg. 2017 Apr 25;1(1):5-10. doi: 10.1002/ags3.12008. eCollection 2017 Apr.
2
[TNM Classification of malignant tumours - Eighth edition: which news?].
Epidemiol Prev. 2017 Mar-Apr;41(2):140-143. doi: 10.19191/EP17.2.P140.034.
3
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.
Int J Clin Oncol. 2018 Feb;23(1):1-34. doi: 10.1007/s10147-017-1101-6. Epub 2017 Mar 27.
4
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2017 Mar;15(3):370-398. doi: 10.6004/jnccn.2017.0036.
5
Cancer Statistics, 2017.
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
6
Adjuvant chemotherapy and prognostic factors in stage II colon cancer--Izmir Oncology Group Study.
Asian Pac J Cancer Prev. 2015;16(6):2413-8. doi: 10.7314/apjcp.2015.16.6.2413.
7
Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.
J Oncol Pract. 2014 Sep;10(5):e360-7. doi: 10.1200/JOP.2013.001309. Epub 2014 Jul 1.
8
Colorectal cancer statistics, 2014.
CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17. doi: 10.3322/caac.21220. Epub 2014 Mar 17.
9
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72. doi: 10.1093/annonc/mdt354.
10
NCCN Clinical Practice Guidelines in Oncology: colon cancer.
J Natl Compr Canc Netw. 2009 Sep;7(8):778-831. doi: 10.6004/jnccn.2009.0056.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验